Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human papillomavirus type 16 minor capsid protein L2 (HPV16 L2) is a structural protein that plays a critical role in the early stages of viral infection, including viral entry, endosomal escape, and retrograde trafficking of the viral genome to the host cell nucleus. Unlike the major capsid protein L1, which is highly type-specific, the N-terminal region of L2 contains highly conserved epitopes (such as the RG1 epitope spanning residues 17-36) that are shared across multiple high-risk and low-risk HPV genotypes. Consequently, HPV16 L2-derived sequences are prime targets for the development of next-generation, broad-spectrum prophylactic vaccines designed to elicit cross-neutralizing antibodies. Additionally, L2-derived sequences are utilized in therapeutic vaccine candidates, such as the fusion protein TA-CIN (comprising HPV16 L2, E6, and E7), to stimulate both humoral and cellular immune responses against HPV-infected and transformed cells. While L2 alone is poorly immunogenic because it does not self-assemble into virus-like particles (VLPs), displaying L2-derived peptides on chimeric VLPs or other molecular scaffolds significantly enhances their immunogenicity and protective efficacy.
Active immunization using HPV16 L2-derived sequences induces cross-neutralizing antibodies that block viral entry and intracellular trafficking, and stimulates cellular immune responses to prevent and treat HPV-associated infections and malignancies.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human papillomavirus type 16 minor capsid protein L2 (HPV16 L2).